CD274 and hepatocellular carcinoma: Recently, advances in the field of immunology have given rise to new cancer treatments - even in HCC - which blockade immune checkpoints (such as PD-1, PD-L1 and CTLA-4) and activate the host immune response against malignant cells (9).